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ABSTRAK
Laporan ini menerangkan kejadian tindak balas ubat clozapine yang jarang berlaku, 
iaitu alahan kutaneus dan angioedema visera, pada seorang pesakit skizofrenia 
yang tidak menunjukkan kesan terhadap rawatan ubat-ubatan yang biasa. Kami 
melaporkan seorang pesakit skizofrenia rintang-rawatan yang mengalami masalah 
alahan pada kulit dan sistem gastro-usus sejurus beliau menerima rawatan ubat 
clozapine. Beliau kemudiannya dirawat dengan kombinasi beberapa ubat-ubatan, 
namun masih mengalami gejala-gejala residual. Manifestasi alahan kepada ubat 
clozapine and strategi perawatan dibincangkan di dalam laporan kes ini. Terdapat 
keperluan yang mendesak bagi penghasilan ubat psikotropik yang setanding 
clozapine untuk merawat pesakit, memandangkan masalah alahan ubat seperti 
laporan kes ini.
Kata kunci: alahan, angioedema, clozapine, skizofrenia
ABSTRACT
This report stresses on the occurrence of a rare adverse reaction to clozapine, i.e. 
allergic cutaneous and visceral angioedema, in a patient with treatment resistant 
schizophrenia (TRS). We report the case of a schizophrenic patient who was 
resistant to treatment and developed an allergic reaction involving her skin and 
gastro-intestinal system upon the commencement of clozapine. She was then 
treated with a combination pharmacotherapy which left some residual symptoms. 
The manifestation of allergic reactions to clozapine and its management strategies 
are discussed in the paper. There is a pressing need to develop a new psychotropic 
which is on par with clozapine.
Keywords:  allergy, angioedema, clozapine, schizophrenia
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irritability and aggression, despite 
being on antipsychotic treatment. 
Since the onset of her illness, she had 
never achieved full symptom remission 
despite being treated with adequate 
dosage and duration of a few anti-
psychotics. She had frequent relapses 
with aggression as the main presenting 
symptom which typically required 
hospitalization. Her first medication 
was the oral risperidone up to 4mg 
daily. Due to persisting symptoms 
and possibility of non-adherence to 
medication, intramuscular (IM) depot 
flupenthixol 20 mg was subsequently 
introduced monthly at first and later 
fortnightly as symptom control was still 
not adequate with monthly injection. 
She who was not known to have any 
drug allergy in the past.
 The diagnosis was revised to 
treatment-resistant schizophrenia and 
clozapine was initiated. Her symptoms 
improved significantly and she was 
discharged following her parent’s 
request with a dose of 50 mg twice 
daily. She developed urticaria in the 
next few days which waxed and waned, 
and it was not reported to the attending 
doctor on her subsequent follow up. 
Clozapine dose was further increased 
another 25 mg during this visit. She 
developed mild fever without other 
symptoms of infections. She visited a 
general practitioner and she was given 
tablet paracetamol. Subsequently, 
she developed periorbital oedema, 
generalized itchy rashes, loss of 
appetite, abdominal pain, vomiting and 
lethargy. She had no respiratory failure. 
She was admitted to the medical ward. 
Eosinophilia (10.6%) was detected 3 
days after hospitalization. She was 
INTRODUCTION
Clozapine was once withdrawn 
from the market in 1978 due to its 
life-threatening adverse reaction 
(Wahlbeck et al. 2000). However, it 
was reintroduced back in 1990 for 
individuals with schizophrenia who 
were resistant to typical neuroleptics 
(Warnez & Alessi-Severini 2014). 
Generally, clozapine is proven to be 
superior to other anti-psychotics (Leucht 
et al. 2009) and its role is also found in 
other psychiatric disorders, possibly 
mania (Ng et al. 2013). Clozapine is 
well accepted and tolerated in most 
individuals (Leucht et al. 2013), except 
few adverse reactions which limits 
its use (McIlwain et al. 2011; Warnez 
& Alessi-Severini 2014). To date, 
clozapine is the only drug licensed for 
for the treatment of treatment-resistant 
schizophrenia (TRS) (Kane & Corell 
2016). 
 Angioedema, a systemic allergic 
reaction to clozapine has not been 
reported widely. We aim to report a 
case of allergic angioedema involving 
skin and gastrointestinal system 
secondary to clozapine in an individual 
with treatment resistant schizophrenia 
(TRS). We highlight the need to develop 
an alternative drug which is as effective 
as clozapine in treating this group of 
patients. 
CASE REPORT
SF, a 22-year-old lady who was 
diagnosed with schizophrenia 3 yrs 
earlier, was hospitalized in February 
2014 due to relapse of her illness with 
symptoms of auditory hallucination, 
persecutory delusion, insomnia, 
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diagnosed with angioedema secondary 
to clozapine. Her family members 
objected to the suggestion for a skin 
prick test for clozapine to confirm the 
diagnosis. She was successfully treated 
with regular intravenous hydrocortisone 
and oral loratadine. She was discharged 
medically after 3 days.  
 Then clozapine was withheld 
and she was started on Tablet 
Haloperidol. Subsequently she was 
tried on quetiapine 800 mg daily with 
combination of haloperidol 5 mg daily 
and IM flupenthixol 40 mg 3 weekly. 
Haloperidol was switched later to tablet 
risperidone and titrated up to 4 mg 
daily. She reported residual symptoms 
all the times despite optimization with 
augmentation and compliance was 
assured.
DISCUSSION
Clozapine is the only drug licensed for 
the treatment of TRS (O’Brien 2004). 
Despite 30-50% significant clinical 
response to clozapine for patients 
with TRS (Chakos et al. 2001), the 
efficacy of clozapine is limited by 
certain life-threatening adverse effects, 
e.g. hypersensitivity, which impose 
challenges in the management in these 
group of patients. There are reports on 
allergic asthmatic reactions (Stoppe et 
al. 1992), allergic vasculitis (Penaskovic 
et al. 2005), angioneurotic edema 
(Mishra et al. 2007)  and a case of late-
onset angioedema (Tatar et al. 2014) 
secondary to clozapine.
 The understanding of immunological 
mechanism of allergic reactions to 
clozapine is based on the hapten 
hypothesis which involves the 
hypersensitivity to the autologous 
protein from the chemically reactive 
metabolites of the drug (Park et al. 
2001). This is a type I hypersensitivity 
reaction which is mediated by Ig E 
antibodies (Lamer et al. 2010). The 
reaction can be systemic or local. 
The local reactions can be manifested 
by cutaneous swelling, nasal or 
conjunctival discharge, bronchial 
asthma and gastroenteritis. The systemic 
reaction can present with anaphylaxis 
and drug rash with eosinophilia and 
systemic symptoms (DRESS) syndrome 
(Warrington & Silviu-Dan 2011). In 
this case, she developed recurrent 
episodes of angioedema involving the 
swelling of skin and possibly mucosal 
of gastrointestinal system (as there 
was no objective investigation e.g. 
colonoscopy, biopsy, done to her).
 Sensitization to clozapine is required 
before a series of reactions to take 
place. Following sensitization, the 
initial response will occur within 
seconds and subsequently subsides 
within an hour, while a late phase 
takes 8 to 12 hrs to develop (Murphy 
et al. 2008). The patient had developed 
transient urticaria following clozapine 
administration in ward. However, 
the presentation was subtle and went 
unreported. She had an exacerbation of 
allergic symptoms after clozapine dose 
was increased a week later.
 Both phases involve powerful 
primary and secondary mediators 
which are responsible in the production 
of the clinical symptoms. The IL-1β, 
TNF-ααand GM-CSF regulate the 
activation, maturation and migration 
of professional antigen presenting cells 
(APC), e.g. epidermal Langerhan’s cells, 
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and mast cells. The activated APCs 
and helper T cells in turn produce 
cytokines, e.g. IL-12 and IL-4 to regulate 
the activation, proliferation and 
differentiation of drug hapten specific 
T-lymphocytes, which the latter elicit 
an inflammatory reaction. Histamine 
and leukotrienes released from mast 
cells play important roles in Ig E 
mediated hypersensitivity reaction. The 
late recruitment of eosinophils which 
directly activate mast cells and sustain 
the immunological reaction (Park et al. 
2000).
 Rechallenge of clozapine has been 
reported in the case of clozapine-
induced leucopenia (Dunk et al. 2006; 
Stanulovic et al. 2013). However, 
there is no literature which discussed 
rechallenging clozapine in the case of 
allergic reaction. The general principle 
of management of drug allergy is to 
withhold the offending medication 
(Frew 2011). Only when there is 
definite medical need for the particular 
medication, there is a strategy of 
induction desensitization or graded 
challenge (Castells 2006). The strategy 
of induction desensitization is discussed 
in hypersensitivity to antibiotics 
(Gruchalla 1998) and aspirin (Wong et 
al. 2000) but was never discussed in 
case of clozapine.
 Among other strategies in clozapine 
intolerant schizophrenic patients, 
there is combination or augmentation 
of various psychotropics and 
electroconvulsive therapy (Porcelli et 
al. 2012). There are reports on high-
dose  aripiprazole (Tripathi et al. 2015) 
and high-dose  quetiapine (Chandrappa 
& Ho 2012) in cases of TRS intolerant 
of clozapine. In this case, she was 
subsequently maintained on high-
dose quetiapine which controlled her 
illness but few psychotic symptoms still 
remained.
 Allergy to clozapine in TRS renders 
psychiatrist no equivalent choice in 
subsequent management. There is 
a dire need for new development of 
pharmacological agent which has 
similar efficacy to clozapine.
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